5-羟基苯并噻唑 | 54013-40-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并三唑类
• 中文名称: 5-羟基苯并噻唑
• 英文名称: 5-hydroxybenzotriazole
• 英文别名: 1H-benzo[1,2,3]triazol-5-ol；1H-benzotriazol-5-ol；5-Hydroxy-1H-benzotriazol；5-Hydroxy-benzotriazol；5-Hydroxybenzotriazole；2H-benzotriazol-5-ol
• CAS: 54013-40-0
• 化学式: C₆H₅N₃O
• 分子量: 135.125
• InChiKey: UVSNFZAOYHOOJO-UHFFFAOYSA-N

物化性质

• 熔点：
  234-235℃
• 沸点：
  473.0±18.0 °C(Predicted)
• 密度：
  1.557±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  61.8
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  5-羟基苯并噻唑 在 盐酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 0.33h， 以85%的产率得到4-nitroso-5-hydroxybenzotriazole
  参考文献：
  名称：

  Synthesis of 5-hydroxy-4-nitrosobenzotriazoles and 6-hydroxy-7-nitrosoindazoles and their splitting into ?-triazolyl- and ?-pyrazolylacrylic acids

  摘要：

  DOI：

  10.1007/bf00478859
• 作为产物：
  描述：

  N-(2-氨基-4-乙氧基苯基)乙酰胺 在 盐酸 、 氢溴酸 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 24.33h， 生成 5-羟基苯并噻唑
  参考文献：
  名称：

  Synthesis of 5-hydroxy-4-nitrosobenzotriazoles and 6-hydroxy-7-nitrosoindazoles and their splitting into ?-triazolyl- and ?-pyrazolylacrylic acids

  摘要：

  DOI：

  10.1007/bf00478859
• 作为试剂：
  描述：

  Boc-L-亮氨酰胺 在 吡啶 、 甲酸 、 5-羟基苯并噻唑 、 三乙胺 、 N,N'-二环己基碳二亚胺 作用下， 以 二氯甲烷 、 氯仿 、 N,N-二甲基甲酰胺 为溶剂， 反应 146.0h， 生成 N-formyl-(L)-methionyl-(L)-leucyl-2-phenylamino-(D,L)-glycine allyl ester
  参考文献：
  名称：

  Synthesis and biological activities of new N-formylated methionyl peptides containing an α-substituted glycine residue

  摘要：

  Small molecular weight peptides related to the well-known chemotactic peptide N-alpha-formyl-methionyl-leucylphenylalanine have been prepared. These compounds were designed to evaluate the requirements in position 3 (phenylalanine). Each analogue containing an alpha-substituted glycine in position 3 was tested for its ability to induce lysosomal enzyme release from cytochalasin B treated human neutrophils. In addition, each analogue was also tested for its ability to antagonize superoxide generation. The results indicate that the analogue N-formyl-methionyl-leucyl-(alpha-anilino)glycine allyl ester is a potent antagonist of superoxide generation. Its ID50's suggest that this compound could be very promising in the field of anti-inflammatory drugs. A hypothetical inhibition mechanism is discussed.

  DOI：

  10.1016/0223-5234(92)90055-6

文献信息

• Nicotinamide benzofused-heterocyclyl derivatives useful as selective inhibitors of pde4 isozymes
  申请人：——

  公开号：US20030186989A1

  公开（公告）日：2003-10-02

  Compounds useful as inhibitors of PDE4 in the treatment of diseases regulated by the activation and degranulation of eosinophils, especially asthma, chronic bronchitis, and chronic obstructive pulmonary disease, of Formula (1.0.0): 1 wherein R 5 and R 6 are taken together to form a moiety of partial Formulas (1.1.1) through (1.1.5): 2 or a pharmaceutically acceptable salt thereof.

  在治疗由嗜酸性粒细胞的激活和脱颗粒调节的疾病，特别是哮喘、慢性支气管炎和慢性阻塞性肺病中作为PDE4抑制剂有用的化合物，其化学式为（1.0.0）： 其中R5和R6一起取代形成部分化学式（1.1.1）至（1.1.5）的基团， 或其药用可接受的盐。
• BICYCLIC HETEROARYL COMPOUNDS AND USES THEREOF FOR THE MODULATION OF HEMOGLOBIN
  申请人：Global Blood Therapeutics, Inc.

  公开号：US20150259296A1

  公开（公告）日：2015-09-17

  Provide herein are compounds and pharmaceutical compositions suitable as modulators of hemoglobin, methods and intermediates for their preparation, and methods for their use in treating disorders mediated by hemoglobin and disorders that would benefit from tissue and/or cellular oxygenation.

  本文提供了适用作为血红蛋白调节剂的化合物和药物组合物，它们的制备方法和中间体，以及在治疗由血红蛋白介导的疾病和需要组织和/或细胞氧合的疾病中使用它们的方法。
• Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them
  申请人：DR. REDDY'S LABORATORIES LIMITED

  公开号：US20030229083A1

  公开（公告）日：2003-12-11

  The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), 1 their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

  本发明涉及具有化学式（I）的新型抗糖尿病、降血脂、抗肥胖和降胆固醇化合物，其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂化物以及含有它们的药学上可接受的组合物。
• COMPOUNDS AND THEIR USE IN MEDICINE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM
  申请人：Debnath Bhuniya

  公开号：US20070142470A1

  公开（公告）日：2007-06-21

  The present invention relates to novel antidiabetic, hypolipidemic, antiobesity and hypocholesterolemic compounds of formula (I), their derivatives, their analogs, their tautomeric forms, their stereoisomers, their polymorphs, their pharmaceutically acceptable salts, their pharmaceutically acceptable solvates and pharmaceutically acceptable compositions containing them.

  本发明涉及一种新型抗糖尿病、降脂、抗肥胖和降胆固醇的化合物，其化学式为(I)，其衍生物、类似物、互变异构体、立体异构体、多晶形态、药学上可接受的盐、药学上可接受的溶剂和含有它们的药学上可接受的组合物。
• Aralkyl Substituted Piperidine or Piperazine Derivatives and Their Use for Treating Schizophrenia
  申请人：Li Jianqi

  公开号：US20110160199A1

  公开（公告）日：2011-06-30

  The present invention discloses an aralkyl substituted piperidine or piperazine derivative and the use of the derivative in preparation of medicaments for treating schizophrenia and correlative psychoneuroses. It is shown by pharmacological tests that the derivative of the present invention has better antischizophrenic effect and less toxicity. Said derivative is a free base or salt of the compound having the following general formula.

  本发明揭示了一种芳基烷基取代的哌啶或哌嗪衍生物，以及该衍生物在制备治疗精神分裂症和相关精神神经症的药物中的应用。药理学测试表明，本发明的衍生物具有更好的抗精神分裂症效果和较小的毒性。所述衍生物是以下一般式化合物的自由碱基或盐。